NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

IMVT

Immunovant Inc

Jul 14 • 11:55AM ET

18.31

Dollar change +0.18
Percentage change 0.97	%

Healthcare • Biotechnology • USA • NASD

Peers: MRNA REGN VRTX BMRN CRSP SRPT NTLA RARE EDIT ARCT

| Held by: VTI IWM VB XBI VXF VBR IWO IBB SCHA VTWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.74	Insider Own	59.89%	Shs Outstand	170.11M	Perf Week	11.48%
Market Cap	3.13B	Forward P/E	-	EPS next Y	-2.85	Insider Trans	19.55%	Shs Float	68.63M	Perf Month	13.34%
Enterprise Value	2.42B	PEG	-	EPS next Q	-0.69	Inst Own	55.50%	Short Float	29.79%	Perf Quarter	23.77%
Income	-413.84M	P/S	-	EPS this Y	-4.63%	Inst Trans	24.22%	Short Ratio	15.87	Perf Half Y	-22.53%
Sales	0.00M	P/B	4.40	EPS next Y	0.31%	ROA	-57.32%	Short Interest	20.44M	Perf YTD	-26.10%
Book/sh	4.16	P/C	4.39	EPS next 5Y	-1.56%	ROE	-62.46%	52W High	34.47 -46.90%	Perf Year	-39.69%
Cash/sh	4.17	P/FCF	-	EPS past 3/5Y	-24.09% -12.18%	ROIC	-58.50%	52W Low	12.72 43.91%	Perf 3Y	330.71%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.23% 4.49%	Perf 5Y	-28.44%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-44.95%	Oper. Margin	-	ATR (14)	0.75	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	11.16	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	69.64	Recom	1.43
Dividend Gr. 3/5Y	- -	Current Ratio	11.16	EPS Q/Q	-23.20%	SMA20	11.52%	Beta	0.66	Target Price	41.57
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	17.74%	Rel Volume	0.94	Prev Close	18.13
Employees	362	LT Debt/Eq	0.00	Earnings	May 29 BMO	SMA200	-14.95%	Avg Volume	1.29M	Price	18.31
IPO	Jun 21, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	10.28% -	Trades		Volume	488,511	Change	0.97%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-10-25	Resumed	Goldman	Neutral	$18
Mar-03-25	Initiated	Jefferies	Hold	$20
Jan-03-25	Downgrade	Wolfe Research	Outperform → Peer Perform
Oct-10-24	Resumed	Raymond James	Outperform	$36
Oct-09-24	Reiterated	Oppenheimer	Outperform	$47 → $53
Mar-28-24	Initiated	Oppenheimer	Outperform	$50
Mar-13-24	Initiated	Goldman	Buy	$50
Feb-20-24	Initiated	JP Morgan	Overweight	$51
Feb-15-24	Initiated	Wolfe Research	Outperform	$55
Dec-12-23	Initiated	Deutsche Bank	Buy	$50
Oct-13-23	Upgrade	UBS	Neutral → Buy	$18 → $55
Sep-26-23	Upgrade	Raymond James	Mkt Perform → Outperform	$40
May-01-23	Initiated	BofA Securities	Buy	$26
Apr-25-23	Initiated	Citigroup	Buy	$28
Mar-31-23	Initiated	Piper Sandler	Overweight	$28
Mar-30-23	Initiated	Stifel	Buy	$28
Feb-15-23	Initiated	Cantor Fitzgerald	Overweight	$30
Feb-13-23	Upgrade	Guggenheim	Neutral → Buy	$30
Jan-03-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$10 → $27
Sep-26-22	Downgrade	UBS	Buy → Neutral	$7 → $5

Show Previous Ratings

Jul-06-25 04:15AM	LifeSci Capital Maintains a Buy on Immunovant (IMVT) With a $50 PT (Insider Monkey)
Jun-02-25 12:00PM	Immunovant (IMVT) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
May-30-25 08:59AM	IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus (Zacks)
May-29-25 07:00AM	Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 (GlobeNewswire) +5.60%
May-09-25 09:02AM	Is Immunovant, Inc. (IMVT) The Best Stock That Will Bounce Back? (Insider Monkey)
06:00AM	Loading…
Apr-22-25 06:00AM	Akeso claims another PD-1/VEGF win; FDA requests more data from Novavax (BioPharma Dive)
Apr-21-25 04:08PM	Immunovant Dives On Its C-Suite Sweep, Narrowed Plans For Leading Drug (Investor's Business Daily)
10:18AM	Immunovant Crumbles After Roivant Sweeps Out Its C-Suite, Unveils Strategic Shift (Investor's Business Daily)
07:00AM	Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjogren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 (GlobeNewswire)
07:00AM	Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sj gren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 (GlobeNewswire)
Apr-08-25 10:05AM	Is Immunovant, Inc. (IMVT) the Best Low Cost Stock to Buy According to Billionaires? (Insider Monkey) -7.51%
Mar-24-25 01:56PM	Argenx: The Magic May Be Already Priced In (SeekingAlpha)
Mar-21-25 12:17PM	Immunovant price target raised to $61 from $58 at Stifel (TipRanks)
Mar-20-25 12:30PM	Immunovants batoclimab shows impressive efficacy in MG, says H.C. Wainwright (TipRanks)
10:19AM	IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success (Zacks)
09:05AM	Loading…
09:05AM	Invesco Health Care Fund Q4 2024 Commentary (SeekingAlpha)
Mar-19-25 05:07PM	Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward (SeekingAlpha)
04:04PM	Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rose. (Investor's Business Daily)
01:12PM	Immunovant will not seek approval for MG therapy, despite hitting endpoints (Clinical Trials Arena)
12:39PM	Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data (Benzinga)
09:26AM	Roivant, Immunovant Succeed In Phase 3. But There's A Twist And Shares Tumbled. (Investor's Business Daily)
07:45AM	Immunovant claims study success for immune disease drug but holds off on submission (BioPharma Dive)
07:45AM	Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies (GlobeNewswire)
Mar-18-25 04:32PM	Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs (GlobeNewswire) -6.14%
Mar-05-25 07:13PM	Immunovant, Inc. (IMVT): Among The Stocks With At Least $30 Million In Insider Spending Recently (Insider Monkey) +5.03%
Mar-04-25 04:50PM	Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity (Investor's Business Daily)
Feb-23-25 01:33PM	Immunovant, Inc. (IMVT): the Most Oversold Pharma Stock to Buy According to Analysts (Insider Monkey)
Feb-22-25 12:53AM	Immunovant, Inc. (IMVT): Is It The Most Oversold Healthcare Stock to Buy Now? (Insider Monkey)
Feb-19-25 04:49PM	Immunovant, Inc. (IMVT): Among Stocks Insiders Spent The Most Money On Recently (Insider Monkey)
Feb-12-25 10:00AM	Roivant Sciences price target lowered to $12 from $13 at BofA (TipRanks)
09:35AM	Loading…
09:35AM	Immunovant (IMVT) Loses -15.47% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Feb-10-25 11:57PM	Q3 2024 Roivant Sciences Ltd Earnings Call (Thomson Reuters StreetEvents)
Feb-06-25 06:30AM	Immunovant Reports Financial Results for the Quarter Ended December 31, 2024 (GlobeNewswire) -9.55%
Jan-30-25 05:03PM	Heres Why Immunovant, Inc. (IMVT) Will Double in 2025 (Insider Monkey)
Jan-17-25 11:10AM	Immunovant, Inc. (IMVT): The Biotech Stock with Biggest Upside Potential (Insider Monkey)
Jan-16-25 08:45AM	Roivant Sciences buys Immunovant Inc. shares and repurchases its own stock for $336.9 million each (GuruFocus.com)
Jan-13-25 08:00AM	Immunovant Announces $450 Million Private Placement (GlobeNewswire)
Dec-20-24 07:20AM	Immunovant price target lowered to $45 from $47 at Wells Fargo (TipRanks)
Nov-21-24 05:31PM	Why Is Immunovant, Inc. (IMVT) Among the Worst Performing Biotech Stocks in 2024? (Insider Monkey)
Nov-13-24 03:05AM	Q2 2024 Roivant Sciences Ltd Earnings Call (Thomson Reuters StreetEvents)
Nov-07-24 06:30AM	Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024 (GlobeNewswire)
Oct-29-24 06:30AM	Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting (GlobeNewswire)
Oct-01-24 09:58AM	Is Immunovant, Inc. (IMVT) the Worst Performing Stock to Buy on the Dip? (Insider Monkey)
Sep-30-24 11:12AM	Is Roivant Sciences Ltd. (NASDAQ:ROIV) The Best NASDAQ Stock Under $50 To Buy? (Insider Monkey)
Sep-09-24 12:54PM	What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday? (Benzinga) -7.61%
09:13AM	Immunovant touts positive Phase II batoclimab data as IMVT-1402 also progresses (Pharmaceutical Technology)
07:00AM	Roivant Provides Update on Graves' Disease Development Program (GlobeNewswire)
03:55AM	Immunovant Provides Update on Graves' Disease Development Program (GlobeNewswire)
Sep-05-24 11:31AM	Why Is Immunovant (IMVT) Up 13.8% Since Last Earnings Report? (Zacks) +9.55%
06:30AM	Immunovant to Host Graves' Disease Program Update on September 9, 2024 (GlobeNewswire)
Aug-09-24 12:20AM	Q1 2025 Roivant Sciences Ltd Earnings Call (Thomson Reuters StreetEvents)
Aug-06-24 04:05PM	Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2024 (GlobeNewswire)
Jun-28-24 11:30AM	Immunovant (IMVT) Down 1.6% Since Last Earnings Report: Can It Rebound? (Zacks)
May-31-24 08:04AM	Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2023 Earnings Call Transcript (Insider Monkey)
02:26AM	Q4 2024 Roivant Sciences Ltd Earnings Call (Thomson Reuters StreetEvents)
May-30-24 04:02PM	After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay (Investor's Business Daily) -10.69%
11:29AM	Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus (Zacks)
07:22AM	Immunovant changes up plans for closely watched autoimmune drugs (BioPharma Dive)
05:53AM	Immunovant shunts next-gen FcRn drug ahead of batoclimab in race to rival Vyvgart (FierceBiotech.com)
May-29-24 09:53PM	IMVT Stock Earnings: Immunovant Misses EPS for Q4 2024 (InvestorPlace)
04:06PM	Biohaven Tumbles After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump (Investor's Business Daily)
04:01PM	Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024 (GlobeNewswire)
10:17AM	Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump (Investor's Business Daily)
May-27-24 06:28PM	Institutional Investors are Betting on Roivant Sciences (NASDAQ:ROIV) (Insider Monkey)
May-13-24 09:55AM	Wall Street Analysts Think Immunovant (IMVT) Could Surge 68.63%: Read This Before Placing a Bet (Zacks)
May-08-24 02:43AM	Greenlight Capital Initiated a Position in Roivant Sciences (ROIV) in Q1 (Insider Monkey)
Apr-24-24 11:33AM	Should You Retain Your Conviction in Rocket Pharmaceuticals (RCKT)? (Insider Monkey)
07:39AM	Should You Hold Immunovant (IMVT)? (Insider Monkey)
Apr-22-24 11:53AM	Here's Why You Should Add Immunovant (IMVT) to Your Portfolio (Zacks)
Apr-17-24 12:00PM	What Makes Immunovant (IMVT) a New Buy Stock (Zacks) -6.48%
Mar-25-24 03:00PM	Wall Streets Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich (InvestorPlace)
Mar-21-24 04:45PM	Argenx, Immunovant Soar As Tourmaline Plummets On A Rival's Lackluster Test Results (Investor's Business Daily)
11:31AM	OmniAb, Inc. (NASDAQ:OABI) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-17-24 05:20PM	11 Oversold Biotech Stocks To Buy Right Now (Insider Monkey)
Mar-14-24 07:04AM	10 Stocks George Soros and Insiders Are Crazy About (Insider Monkey)
Mar-13-24 11:30AM	Why Is Immunovant, Inc. (IMVT) Down 14.7% Since Last Earnings Report? (Zacks)
Mar-12-24 07:30AM	Immunovant Awarded U.S. Patent for IMVT-1402 (GlobeNewswire)
Mar-08-24 09:35AM	Here's Why Immunovant, Inc. (IMVT) is Poised for a Turnaround After Losing -8.02% in 4 Weeks (Zacks)
Feb-26-24 03:04PM	3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024 (InvestorPlace)
Feb-23-24 11:22PM	Immunovant Inc CFO Eva Barnett Sells 2,930 Shares (GuruFocus.com)
Feb-14-24 04:35AM	Immunovant Inc (IMVT) Reports Fiscal Q3 Results: Expands Clinical Programs Amid Rising R&D Costs (GuruFocus.com)
12:29AM	Q3 2024 Roivant Sciences Ltd Earnings Call (Thomson Reuters StreetEvents)
Feb-13-24 07:26AM	Immunovant (IMVT) Up 3% as Q3 Earnings Top, Pipeline in Focus (Zacks)
Feb-12-24 07:00AM	Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023 (GlobeNewswire)
Feb-06-24 02:38PM	7 Russell 2000 Stocks to Buy for the Next Bull Run: February 2024 (InvestorPlace)
Jan-22-24 06:07AM	Should You Invest in Immunovant (IMVT)? (Insider Monkey)
Jan-19-24 04:39PM	3 Top-Rated Russell 2000 Stocks Wall Street Analysts Are Loving Now: January 2024 (InvestorPlace)
Jan-13-24 03:02AM	Immunovant Inc CFO Eva Barnett Sells 3,515 Shares (GuruFocus.com)
Jan-03-24 08:00AM	Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -6.33%
Dec-26-23 10:01AM	Immunovant (IMVT) Rose on Positive Clinical Trial (Insider Monkey) +6.53%
Dec-21-23 04:09PM	Immunovant Scores Much-Needed Win Following Argenx-Led Sell-off (Investor's Business Daily) +8.07% +6.09%
11:00AM	Immunovant (IMVT) Up on Upbeat Initial Batoclimab GD Study Data (Zacks)
10:57AM	Autoimmune Disease Player Immunovant's Investigational Drug For Immune System Disorder Shows Response Rates Of Over 50% (Benzinga)
06:49AM	Immunovant stakes claim for FcRn niche, posting midphase Graves' data and plotting next steps (FierceBiotech.com)
Dec-20-23 04:30PM	Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease (GlobeNewswire) -12.84%
04:30PM	Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease (GlobeNewswire)
Dec-19-23 10:16AM	11 Stocks Insiders and Billionaires Are Crazy About (Insider Monkey)
Dec-01-23 01:01AM	Here's Why Immunovant (IMVT) Outperformed in Q3 (Insider Monkey)
Nov-29-23 10:22AM	Immunovant (IMVT) Up on Positive Initial IMVT-1402 MAD Study Data (Zacks) +6.19%
Nov-28-23 07:00AM	Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential (GlobeNewswire) +7.36%

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Geffner Michael	Chief Medical Officer	Jul 09 '25	Sale	17.24	1,160	19,998	224,210	Jul 11 04:15 PM
Stout Jay S	Chief Technology Officer	Jul 09 '25	Sale	17.24	1,519	26,188	207,724	Jul 11 04:13 PM
WILLIAM MACIAS	Officer	Jun 25 '25	Proposed Sale	15.83	30,000	474,861		Jun 25 04:02 PM
WILLIAM MACIAS	Officer	Jun 13 '25	Proposed Sale	15.57	50,000	778,490		Jun 13 05:34 PM
WILLIAM MACIAS	Officer	Jun 03 '25	Proposed Sale	15.61	80,000	1,248,616		Jun 03 05:42 PM
GEORGE V MIGAUSKY	Former Director	May 21 '25	Proposed Sale	14.58	21,812	318,047		May 21 04:24 PM
GEORGE V MIGAUSKY	Former Director	May 19 '25	Proposed Sale	14.58	28,188	410,908		May 19 04:40 PM
Stout Jay S	Chief Technology Officer	Apr 23 '25	Sale	14.79	1,925	28,471	209,243	Apr 25 04:17 PM
Geffner Michael	Chief Medical Officer	Apr 23 '25	Sale	14.79	2,349	34,742	225,370	Apr 25 04:15 PM
Barnett Eva Renee	Chief Financial Officer	Apr 16 '25	Sale	14.89	2,993	44,566	396,774	Apr 17 04:08 PM
Salzmann Peter	Chief Executive Officer	Apr 16 '25	Sale	14.89	8,321	123,900	1,178,191	Apr 17 04:07 PM
Salzmann Peter	Chief Executive Officer	Apr 09 '25	Sale	12.99	28,094	364,941	1,186,512	Apr 11 04:05 PM
Fromkin Andrew J.	Director	Mar 07 '25	Sale	19.60	8,000	156,769	91,913	Mar 11 04:18 PM
ANDREW J FROMKIN	Director	Mar 07 '25	Proposed Sale	19.52	8,000	156,160		Mar 07 04:17 PM
Macias William L.	Chief Medical Officer	Feb 19 '25	Sale	20.86	2,055	42,867	357,353	Feb 21 04:06 PM
Barnett Eva Renee	Chief Financial Officer	Feb 19 '25	Sale	20.86	2,814	58,700	321,952	Feb 21 04:05 PM
Salzmann Peter	Chief Executive Officer	Feb 19 '25	Sale	20.86	15,439	322,058	948,786	Feb 21 04:04 PM
MARK S LEVINE	Former Affiliate	Feb 14 '25	Proposed Sale	20.16	69,763	1,406,757		Feb 14 04:11 PM
MARK S LEVINE	Former Affiliate	Feb 11 '25	Proposed Sale	19.54	29,196	570,437		Feb 11 04:11 PM
Stout Jay S	Chief Technology Officer	Jan 22 '25	Sale	23.59	2,195	51,780	139,991	Jan 24 04:23 PM
Geffner Michael	Chief Medical Officer	Jan 22 '25	Sale	23.59	2,657	62,679	132,314	Jan 24 04:22 PM
Macias William L.	Chief Medical Officer	Jan 15 '25	Sale	23.83	2,383	56,782	359,408	Jan 17 04:07 PM
Barnett Eva Renee	Chief Financial Officer	Jan 15 '25	Sale	23.83	2,298	54,757	324,766	Jan 17 04:05 PM
Salzmann Peter	Chief Executive Officer	Jan 15 '25	Sale	23.83	8,767	208,900	964,225	Jan 17 04:04 PM
Roivant Sciences Ltd.	Director	Jan 13 '25	Buy	20.00	16,845,010	336,900,200	96,650,341	Jan 15 04:36 PM
Barnett Eva Renee	Chief Financial Officer	Jan 08 '25	Sale	24.10	4,105	98,930	327,064	Jan 10 04:12 PM
Salzmann Peter	Chief Executive Officer	Jan 08 '25	Sale	24.10	5,105	123,030	972,992	Jan 10 04:11 PM
Pande Atul	Director	Dec 02 '24	Sale	28.54	7,750	221,185	86,663	Dec 04 04:22 PM
Hughes Douglas J.	Director	Dec 02 '24	Sale	28.54	5,425	154,830	119,585	Dec 04 04:20 PM
DOUGLAS J. HUGHES	Officer	Dec 02 '24	Proposed Sale	28.20	5,425	152,985		Dec 02 04:33 PM
ATUL CHANDRA PANDE	Director	Dec 02 '24	Proposed Sale	28.20	7,750	218,550		Dec 02 04:33 PM
Levine Mark S.	Chief Legal Officer	Nov 20 '24	Sale	25.45	3,650	92,892	319,228	Nov 22 04:12 PM
Macias William L.	Chief Medical Officer	Nov 20 '24	Sale	25.45	3,353	85,334	361,791	Nov 22 04:11 PM
Barnett Eva Renee	Chief Financial Officer	Nov 20 '24	Sale	25.45	4,174	106,228	331,169	Nov 22 04:09 PM
Salzmann Peter	Chief Executive Officer	Nov 20 '24	Sale	25.45	16,692	424,811	978,097	Nov 22 04:08 PM
Levine Mark S.	Chief Legal Officer	Oct 23 '24	Sale	29.53	4,361	128,780	322,878	Oct 25 04:25 PM
Geffner Michael	Chief Medical Officer	Oct 23 '24	Sale	29.53	3,189	94,171	134,971	Oct 25 04:23 PM
Stout Jay S	Chief Technology Officer	Oct 23 '24	Sale	29.53	2,740	80,912	142,186	Oct 25 04:21 PM
Salzmann Peter	Chief Executive Officer	Oct 16 '24	Sale	28.79	9,095	261,845	994,789	Oct 18 04:31 PM
Macias William L.	Chief Medical Officer	Oct 16 '24	Sale	28.79	3,188	91,783	365,144	Oct 18 04:30 PM
Levine Mark S.	Chief Legal Officer	Oct 16 '24	Sale	28.79	2,860	82,339	327,239	Oct 18 04:28 PM
Barnett Eva Renee	Chief Financial Officer	Oct 16 '24	Sale	28.79	3,271	94,172	335,343	Oct 18 04:27 PM
Barnett Eva Renee	Chief Financial Officer	Oct 09 '24	Sale	29.56	5,162	152,589	338,614	Oct 11 04:04 PM
Salzmann Peter	Chief Executive Officer	Oct 09 '24	Sale	29.56	4,460	131,838	1,003,884	Oct 11 04:02 PM
Levine Mark S.	Chief Legal Officer	Aug 21 '24	Sale	31.86	3,295	104,976	330,099	Aug 23 04:15 PM
Macias William L.	Chief Medical Officer	Aug 21 '24	Sale	31.86	3,027	96,437	368,332	Aug 23 04:14 PM
Barnett Eva Renee	Chief Financial Officer	Aug 21 '24	Sale	31.86	3,768	120,045	343,776	Aug 23 04:11 PM
Butchko Julia G.	Chief Development Officer	Aug 21 '24	Sale	31.86	3,027	96,437	440,959	Aug 23 04:10 PM
Salzmann Peter	Chief Executive Officer	Aug 21 '24	Sale	31.86	15,068	480,052	1,008,344	Aug 23 04:07 PM
Stout Jay S	Chief Technology Officer	Jul 24 '24	Sale	27.76	2,813	78,089	144,926	Jul 26 04:20 PM
Geffner Michael	Chief Medical Officer	Jul 24 '24	Sale	27.76	3,456	95,939	138,160	Jul 26 04:19 PM
Levine Mark S.	Chief Legal Officer	Jul 24 '24	Sale	27.76	4,015	111,456	333,394	Jul 26 04:17 PM
Levine Mark S.	Chief Legal Officer	Jul 17 '24	Sale	29.69	2,505	74,382	337,409	Jul 19 05:42 PM
Macias William L.	Chief Medical Officer	Jul 17 '24	Sale	29.69	3,044	90,386	371,359	Jul 19 05:41 PM
Barnett Eva Renee	Chief Financial Officer	Jul 17 '24	Sale	29.69	3,123	92,733	347,544	Jul 19 05:39 PM
Butchko Julia G.	Chief Development Officer	Jul 17 '24	Sale	29.69	2,867	85,132	443,986	Jul 19 05:38 PM
Salzmann Peter	Chief Executive Officer	Jul 17 '24	Sale	29.69	8,685	257,887	1,023,412	Jul 19 05:36 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IMVT

Immunovant Inc

Upgrade your FINVIZ experience